1.
Risk prediction models: II. External validation, model updating, and impact assessment
by Moons, Karel G M
Heart, 2012, Vol.98 (9), p.691-698

2.
Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker
by Moons, Karel G M
Heart, 2012, Vol.98 (9), p.683-690

3.
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
by Anderson, Simon G
Heart (British Cardiac Society), 2016, Vol.102 (21), p.1750-1756
